Louise Rodino-Klapac
Vermogen: 975 059 $ op 31-05-2026
Vermogen: 975 059 $ op 31-05-2026
Louise Rodino-Klapac, oprichter van Myonexus Therapeutics, Inc., zit in de raad van bestuur van Alliance for Regenerative Medicine en Aavantibio, Inc. en is Chief Scientific Officer & Executive VP bij Sarepta Therapeutics, Inc., lid van de American Academy of Neurology en lid van de American Society of Gene & Cell Therapy. Daarvoor was zij Chief Scientific Officer bij Myonexus Therapeutics, Inc. en Head-Laboratory for Gene Therapy Research bij het Nationwide Children's Hospital. Zij behaalde een bachelor aan King's College (Pennsylvania) en een doctoraat aan The Ohio State University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-04-2026 | 54.564 ( 0,05% ) | 975 059 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 14-12-2020 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Directeur/Bestuurslid | 01-01-2021 |
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services Operates as medical and professional organization that represents researchers and scientists devoted to the discovery | Corporate Officer/Principal | - |
American Academy of Neurology
American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services Operates a professional society which represents neurologists and neuroscientists | Corporate Officer/Principal | - |
| Bedrijven | Functie | Einde |
|---|---|---|
Nationwide Children's Hospital
Nationwide Children's Hospital Hospital/Nursing ManagementHealth Services Operates children's hospitals | Corporate Officer/Principal | 01-06-2019 |
Myonexus Therapeutics, Inc.
Myonexus Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for limb-girdle muscular dystrophies | Oprichter | 01-04-2019 |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Directeur/Bestuurslid | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 9 |
|---|---|
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
King's College (Pennsylvania)
King's College (Pennsylvania) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Ohio State University
The Ohio State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Academy of Neurology
American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services Operates a professional society which represents neurologists and neuroscientists | Commercial Services |
Nationwide Children's Hospital
Nationwide Children's Hospital Hospital/Nursing ManagementHealth Services Operates children's hospitals | Health Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services Operates as medical and professional organization that represents researchers and scientists devoted to the discovery | Commercial Services |
Myonexus Therapeutics, Inc.
Myonexus Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for limb-girdle muscular dystrophies | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau